Former Allergan CEO David Pyott will not get a seat on the board at Actavis after all, now that their $70 billion merger is done.
Bayer says it plans to grow its main healthcare division by 6% annually over the next 3 years.
Medtronic invests in anti-leg-cramp drug maker Flex Pharma's initial public offering.
Pfizer looks to bolster its generics footprint with a $15 billion bid for Hospira.
Allergan agrees to a $66 billion takeover bid from Actavis, thwarting a hostile takeover bid by Valeant Pharmaceuticals and William Ackman's Pershing Square Capital Management.
Allergan is close to sealing a deal worth nearly $66 billion with Actavis and giving the slip to a hostile takeover bid from Valeant Pharmaceuticals and William Ackman's Pershing Square hedge fund.
Capricor Therapeutics acquires Medtronic's patent rights for the formulation and delivery of natriuretic peptides to treat heart failure.
Capricor Therapeutics said it acquired Medtronic's (NYSE:MDT) patent rights for the formulation and delivery of natriuretic peptides.